PGNX : Summary for Progenics Pharmaceuticals Inc. - Yahoo Finance

U.S. Markets closed

Progenics Pharmaceuticals, Inc. (PGNX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.25+0.43 (+3.97%)
At close: 4:00PM EDT

11.25 0.00 (0.00%)
After hours: 4:20PM EDT

People also watch
NBIXARRYRIGLSGYPIMMU
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close10.82
Open10.85
Bid5.14 x 100
Ask0.00 x
Day's Range10.81 - 11.26
52 Week Range3.91 - 11.72
Volume957,236
Avg. Volume1,319,691
Market Cap789.64M
Beta3.94
PE Ratio (TTM)75.00
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
    Capital Cube5 days ago

    Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017

    Categories: Yahoo Finance Get free summary analysis Progenics Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Progenics Pharmaceuticals, Inc. – Seattle Genetics, Inc., Nektar Therapeutics, Sucampo Pharmaceuticals, Inc. Class A, Astrazeneca PLC Sponsored ADR, Johnson & Johnson and Ironwood Pharmaceuticals, Inc. Class A (SGEN-US, ... Read more (Read more...)

  • Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
    Capital Cube8 days ago

    Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017

    Categories: Yahoo Finance Get free summary analysis Progenics Pharmaceuticals, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Progenics Pharmaceuticals, Inc. – Seattle Genetics, Inc., Nektar Therapeutics, Sucampo Pharmaceuticals, Inc. Class A, Astrazeneca PLC Sponsored ADR, Johnson & Johnson and Ironwood Pharmaceuticals, Inc. Class A (SGEN-US, ... Read more (Read more...)

  • Associated Press13 days ago

    Progenics reports 4Q loss

    On a per-share basis, the New York-based company said it had a loss of 10 cents. The biopharmaceutical company posted revenue of $4.7 million in the period. For the year, the company reported net income ...